bpc-157 clinical trials 2025 What is BPC-157? dihexa clinical trials humans BPC
Description
Many patients notice initial digestive improvements within 1-2 weeks of starting BPC-157 oral therapy, with continued enhancement throughout the protocol duration
Correcting a true B12 deficiency can improve energy and exercise capacity, which may indirectly help with diet and training
Treatment with NNMT inhibitors rescues these age-related deficits by restoring NAD+ availability and supporting metabolic reprogramming during myogenic differentiation
Why It Was in Category 2 The FDA cited significant safety concerns when placing BPC-157 in Category 2, effectively restricting compounding pharmacy access
Gastroprotective signaling pathway activity
